Abstract
Objective. To study the effect of mexidol as part of complex therapy on the perception of life in patients with heart failure (HF). Methods. The open randomized study included 60 comorbid patients with coronary heart disease (CHD) and stable chronic heart failure (CHF) with cognitive impairment (CN) <24 points on the Montreal Cognitive Function Assessment Scale (MoCA). The average age of patients was 73.4±8.6 years, 53% were male, the average left ventricular ejection fraction was 43.5±10.6%. 30 patients were included in the group of standard CHF therapy with additional administration of mexidol (500 mg intravenously once a day for 14 days, then 250 mg 3 times a day for 8 weeks) and 30 patients in the standard therapy group. Initially and at the end of the study, an assessment of the perception of life was carried out. The survey included 4 main areas: (1) the relative importance of disease-related goals, (2) issues related to living with heart failure (HF) and taking HF medications, (3) decision-making process related to the use of HF medications, and (4) awareness and concerns about available HF medications. Results. The main problems associated with living with HF and taking medications for HF, all patients, regardless of the treatment group, initially and after 10 weeks of therapy noted the effectiveness of treatment in reducing the symptoms of HF, in reducing the number of hospitalizations for HF and mortality. Other problems that were most relevant for patients were the presence of shortness of breath, swelling and fatigue, followed by anxiety about the disease, the need to take a large number of medications, the inability to do what they wanted. The patients were least concerned about depression, inability to work, the need for help from relatives, the cost of medications and the struggle with side effects of medications. The beneficial effect of mexidol as part of complex therapy on the patient’s perception of life with HF is shown. Improving the cognitive status of the patient on mexidol treatment contributes to rethinking the main goals of treatment to more global ones — the effectiveness of the drug in reducing mortality, the number of hospitalizations and symptoms of HF, reducing the number of life-limiting factors in the form of edema and shortness of breath, and as a result, increasing the physical activity of the patient. The only limiting factor is the need to take a large number of medications daily and the desire to reduce their number. Conclusion. There is a discrepancy between the priorities of patients and awareness of the optimal drug therapy that has proven its effectiveness. Patients are not familiar with HF therapy, and those who are familiar have concerns about its safety and effectiveness. Long-term sequential therapy with Mexidol when added to standard therapy in patients with chronic heart failure of functional class II-III (according to the NYHA classification) with moderate cognitive status disorders, in addition to a significant improvement in cognitive status and quality of life parameters, favorably affects the patient’s perception of life with heart failure.

This publication has 17 references indexed in Scilit: